

Long COVID: What Will It Take to Accelerate Therapeutic Progress?

Virtual event, February 21, 2023; 1-4:30pm ET

Agenda

Opening Remarks

Cartier Esham, Ph.D., Chief Science Officer, BIO

US Senator, Tim Kaine

Rachel L. Levine, M.D., Admiral, U.S. Public Health Service, Assistant Secretary for Health

U.S. Department of Health and Human Services

What is Long COVID?

Patient perspective: Lisa McCorkell, M.P.P., Patient-led Research Collaborative

Disease spectrum: David Putrino, Ph.D., Mt. Sinai School of Medicine

Epidemiology: Priti Patel, M.D., M.Ph., The Centers for Disease Control and Prevention (CDC)

Economic burden: Katie Bach, M.B.A., Brookings Institution

Causes, pathways and biological targets

Pathophysiology: Akiko Iwasaki, Ph.D., Yale School of Medicine

Potential biological targets: Michael VanElzakkar, Ph.D., PolyBio; Massachusetts General Hospital

Break: 3:00pm (10 min)

Clinical Studies and Emerging Therapeutic Approaches

NIH Recover Initiative: Walter Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke (NINDS)

AIM Immunotech: Thomas Equels, J.D., CEO

Axcella Therapeutics: Margaret Koziel, M.D., CMO

IncellDx: Bruce Patterson, M.D., CEO

Tonix Pharmaceuticals: Seth Lederman, M.D., CEO

Accelerating Therapeutic progress: Panel discussion + QA

Oved Amitay, R.Ph., CEO Solve M.E. (moderator)

Christopher Austin, M.D., CEO-Partner, Flagship Pioneering

Julie Louise Gerberding, M.D., M.P.H., CEO, Foundation for the National Institutes of Health (FNIH)

Closing and next steps

Cartier Esham, Ph.D., Chief Science Officer, BIO

